This overview summarises available pharmacokinetic data on budesonide capsules (Entocort™
EC), approved for the treatment of mild-to-moderate active Crohn’s disease involving …

The pulmonary and systemic availability of budesonide after inhalation from a dry powder
inhaler, Turbuhaler, and from a pressurized metered-dose inhaler (P-MDI) were compared in …

Budesonide is a highly potent non-halogenated glucocorticoid intended for the local treatment
of lung disease. Budesonide is designed to have a high ratio between local and systemic …

… where mucociliary clearance is most efficient. When drug-induced bronchodilation is achieved,
deposition and uptake becomes more peripheral, and because there is less mucociliary …

Delivering therapeutic agents to the lungs requires a deep understanding of the kinetics and
dynamics of drugs in this biologically and physiologically complex system. In this chapter …

… The aim of the present paper is to review the preclinical and human experimental evidence
supporting the esterification of BUD, and to discuss the clinical implications this may have on …

… Conclusions Budesonide and fluticasone differ in their pharmacokinetic properties in that
although clearance is the same, the rate of uptake and elimination is slower for fluticasone. …

Aims The present study was undertaken to see whether the difference in plasma cortisol
suppression between single and repeated dosing of fluticasone propionate (FP) can be …

… This investigation, previously only presented as abstracts or summarized in reviews, is the
first to delineate the pharmacokinetics, intestinal transport and release of budesonide after …

Budesonide, a topically potent glucocorticoid, was administered to 4 healthy volunteers by
iv infusion and by nasal instillation of 100 µg tritium-labelled drug. Plasma was analyzed by …